de Oliveira Carlos Eduardo Coral, Amarante Marla Karine, Perim Aparecida de Lourdes, Ozawa Patricia Midori Murobushi, Hiroki Carlos, Freire Vitiello Glauco Akelinghton, Losi Guembarovski Roberta, Watanabe Maria Angelica Ehara
Laboratory of Study and Application of DNA Polymorphisms, Department of Pathological Sciences, Biological Sciences Center, State University of Londrina, Rodovia Celso Garcia Cid, (PR 445), Km 380, 86051-970 Londrina, PR, Brazil.
Laboratory of Hematology, Department of Pathology, Clinical and Toxicological Analysis, Health Sciences Center, State University of Londrina, Londrina, PR, Brazil.
Adv Hematol. 2014;2014:924030. doi: 10.1155/2014/924030. Epub 2014 Apr 13.
Acute lymphoblastic leukemia (ALL) is a malignant disorder that originates from one single hematopoietic precursor committed to B- or T-cell lineage. Ordinarily, these cells express CCR5 chemokine receptor, which directs the immune response to a cellular pattern and is involved in cancer pathobiology. The genetic rs333 polymorphism of CCR5 (Δ32), results in a diminished receptor expression, thus leading to impaired cell trafficking. The objective of the present study was to investigate the effect of CCR5 chemokine receptor rs333 polymorphism in the pathogenesis of ALL. The genotype distribution was studied in 79 patients and compared with 80 control subjects, in a childhood population of Southern Brazil. Genotyping was performed using DNA samples amplified by polymerase chain reaction with sequence-specific primers (PCR-SSP). The homozygous (Δ32/Δ32) deletion was not observed in any subject involved in the study. Heterozygous genotype was not associated with ALL risk (OR 0.7%; 95% CI 0.21-2.32; P > 0.05), nor recurrence status of ALL (OR 0.86; 95% CI 0.13-5.48; P > 0.05). This work demonstrated, for the first time, no significant differences in the frequency of the CCR5/Δ32 genotype between ALL and control groups, indicating no effect of this genetic variant on the ALL susceptibility and recurrence risk.
急性淋巴细胞白血病(ALL)是一种恶性疾病,起源于单一的造血前体细胞,该细胞定向分化为B细胞或T细胞谱系。通常情况下,这些细胞表达CCR5趋化因子受体,该受体引导免疫反应针对细胞模式,并参与癌症病理生物学过程。CCR5基因的rs333多态性(Δ32)导致受体表达减少,从而导致细胞迁移受损。本研究的目的是探讨CCR5趋化因子受体rs333多态性在ALL发病机制中的作用。在巴西南部的儿童人群中,对79例患者的基因型分布进行了研究,并与80例对照受试者进行了比较。使用序列特异性引物通过聚合酶链反应(PCR-SSP)扩增的DNA样本进行基因分型。在参与研究的任何受试者中均未观察到纯合子(Δ32/Δ32)缺失。杂合子基因型与ALL风险无关(比值比0.7%;95%置信区间0.21-2.32;P>0.05),也与ALL的复发状态无关(比值比0.86;95%置信区间0.13-5.48;P>0.05)。这项研究首次表明,ALL组和对照组之间CCR5/Δ32基因型频率没有显著差异,表明该基因变异对ALL易感性和复发风险没有影响。